Trial reportPediatric research2026
Saccharomyces boulardii's impact on pediatric diarrhea-predominant irritable bowel syndrome: animal model findings.
Trial report in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Yeasts in the gastrointestinal tract.FEMS yeast research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the therapeutic effect of Saccharomyces boulardii in children with IBS-D, focusing on its mechanism of action associated with gut microbiota regulation and immune response.
methodsA total of 60 children were randomly divided into Saccharomyces boulardii treatment group and placebo treatment group. Treatment continued for 14 days, during which the severity of IBS symptoms and associated biochemical markers were monitored. At the same time, the mechanism of action of Saccharomyces boulardii therapy was explored through animal experiments and microbial analysis.
resultsClinical data have shown that Saccharomyces boulardii treatment significantly improves IBS-D symptoms in children, as evidenced by the reduction in IBS symptom severity scale score and normalization of stool morphology. Animal mechanistic studies have revealed the role of Saccharomyces boulardii in regulating gut microbiota diversity and reducing inflammatory markers.
conclusionSaccharomyces boulardii shows potential as an effective probiotic supplement for treating pediatric IBS-D, providing benefits through modulation of gut microbiota and reduction of inflammation. IMPACT: This study investigated the efficacy and mechanism of Saccharomyces boulardii in the treatment of children with diarrheal irritable bowel syndrome (IBS-D) through clinical trials and animal models. The specific role of Saccharomyces boulardii in the treatment of IBS-D is described, supplementing the evidence in the existing literature. Through animal experiments and microbial analysis, its role in regulating intestinal microbiota and immune response was further elucidated. The results suggest that Saccharomyces boulardii can treat IBS-D in children, providing clinicians with new treatment options and stimulating more research into the role of probiotics in regulating gut health and immune response.
Indexed as
Identifiers
41214290What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.